Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma.
about
Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerIncreased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study.Combination of intratumoral invariant natural killer T cells and interferon-gamma is associated with prognosis of hepatocellular carcinoma after curative resection.Recurrence-associated pathways in hepatitis B virus-positive hepatocellular carcinoma.Trial watch: Prognostic and predictive value of the immune infiltrate in cancerEnhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.PD-1(+) and Foxp3(+) T cell reduction correlates with survival of HCC patients after sorafenib therapyClinical implications of basic research in hepatocellular carcinoma.PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma.Hepatocellular carcinoma: systemic therapies and future perspectives.Immunotherapy in hepatocellular carcinoma: Primed to make a difference?PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.Vaccines for established cancer: overcoming the challenges posed by immune evasion.Survival impact of lymphocyte infiltration into the tumor of hepatocellular carcinoma in hepatitis B virus-positive or non-B non-C patients who underwent curative resection.Liver-infiltrating CD11b(-)CD27(-) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression.Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas.Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.Role of nonresolving inflammation in hepatocellular carcinoma development and progression.Immunotherapy of hepatocellular carcinomaImmune Gene Expression Profile in Hepatocellular Carcinoma and Surrounding Tissue Predicts Time to Tumor RecurrenceMolecular Targets in Hepatocarcinogenesis and Implications for Therapy
P2860
Q33717146-B7B95D06-3A22-4009-BE5F-8935388C9BEAQ34270064-3360322C-1748-4CD0-9CB3-5C66A70A3447Q34658445-68E52872-2AFB-4685-B6F0-ECDD7FD8ED6DQ34934974-2E4D105D-1B6C-4678-B0E9-70DC2994E9BFQ35608091-FEBEDC74-09B7-4860-9AE3-281EDA000A97Q36456483-0738545A-F14D-460F-AFC1-040FE4050366Q36871188-54C354C9-E53B-4B63-8D50-EDD0BE8881BDQ36951719-A05B04BD-D5DB-4F96-8ED3-D2D4FBDAA88AQ37179971-FFFFE7F0-36F7-4025-B0C2-88B0675704A8Q37289933-AC349977-4BB9-4921-945C-75C9801B489EQ37705021-C5D6BDAC-0E91-4AA5-A51C-5A1E34ED6F6EQ38246965-862E60A9-6C3D-416C-93C2-6EFD4AF50AC4Q38625948-A3F946B4-63ED-4E9D-AE1B-7D3E3338C528Q38642853-43BDD0AC-3E2B-45BF-87AC-C8FC2996FD80Q38769021-55B32DF6-786E-40A5-9019-52F7B38D467DQ40127743-40806BB1-D4CB-449B-A198-6AB2D5795897Q40692653-F9F18064-4152-4F8E-AB80-3489BCDB4082Q41472059-C13DF491-7D73-418E-85F1-DCE7EAFB34D7Q41543718-BB8E4FC0-3FE6-4566-A128-D0DA4A065581Q47119885-B5ECD5F5-C119-447A-BFF4-D462F935D8F6Q47576215-26DE2228-43DB-4AF2-A483-3BEE6CE697D9Q55288642-348806D0-EA3D-434F-88F6-51911477726CQ56896669-64533A42-8F7D-4A70-A6F3-EDBF8F75DA55Q57494809-50F089F7-D0D3-4CC9-AAFB-551B471AD3E7Q58784853-27FCB703-EA69-44C8-96DE-5AD0777F3500
P2860
Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Immunological and molecular co ...... for hepatocellular carcinoma.
@ast
Immunological and molecular co ...... for hepatocellular carcinoma.
@en
Immunological and molecular co ...... for hepatocellular carcinoma.
@nl
type
label
Immunological and molecular co ...... for hepatocellular carcinoma.
@ast
Immunological and molecular co ...... for hepatocellular carcinoma.
@en
Immunological and molecular co ...... for hepatocellular carcinoma.
@nl
prefLabel
Immunological and molecular co ...... for hepatocellular carcinoma.
@ast
Immunological and molecular co ...... for hepatocellular carcinoma.
@en
Immunological and molecular co ...... for hepatocellular carcinoma.
@nl
P2093
P2860
P50
P1433
P1476
Immunological and molecular co ...... n for hepatocellular carcinoma
@en
P2093
Claudia Schianchi
Cristina Rota
Enrico Maria Silini
Guido Pelosi
Massimo Pilli
Nicoletta Campanini
Paolo Soliani
Tommaso Trenti
P2860
P304
P356
10.1371/JOURNAL.PONE.0032493
P407
P577
2012-03-02T00:00:00Z